HomeSkip to content

Woman on phone Treatment Phoneline 0808 800 6013 Mon-Wed 12-4pm

Avoiding & managing side effects – May 2008

Skin rash


About skin rash

Many drugs are associated with rash including: abacavir (Ziagen and Trizivir), FTC (Emtriva), nevirapine (Viramune) and efavirenz (Sustiva), fosamprenavir (Lexiva/Telzir), atazanavir (Reyataz), tipranavir (Aptivus) and T-20 (enfuvirtide, Fuzeon).

Man with spotty faceAlthough many drugs are linked to rash, the severity of rash and how long it lasts varies considerably.

If you develop a rash during the first few weeks of therapy with some drugs you must report this immediately to your doctor. This is because it can sometimes lead to very serious reactions. These drugs are abacavir (Ziagen, and in Trizivir and Kivexa), nevirapine (Viramune), efavirenz (Sustiva), fosamprenavir (Lexiva) and T-20 (enfuvirtide, Fuzeon).

Other rashes are more likely to be mild and disappear without treatment, or can be easily treated with antihistamine drugs such as cetirizine (Zirtek) or loratadine (Clarityn).

Atazanavir can cause a mild rash during the first two months in 10% of people but this disappears without additional treatment within a few weeks.

FTC studies reported rash on the palms of the hands or feet in up to 10% of African Americans, but these have been reported less frequently since the drug has been licensed.

Although antihistamines are available over the counter, it is important that you check with your doctor or pharmacist before taking them, as there can be interactions with HIV drugs.

Rashes can also occur as a reaction from exposure to the sun, and will normally resolve. Any rash that makes you feel sick may not be a side effect but a symptom of an underlying disease (such as scabies).

Other things that can help

Nevirapine and efavirenz rashes

Up to 20% of people using nevirapine, and 5% of people using efavirenz, will experience a mild to moderate rash in the first weeks of treatment. For most people this disappears over the next few weeks and they experience no further side effects.

Women are at a higher risk of rash with nevirapine than men. Women should not start treatment with nevirapine if their CD4 count is over 250 cells/mm3 or men if their CD4 count is over 400 cells/mm3.

Nevirapine needs to be dosed in two stages. For the first two weeks, you should only take one 200mg tablet, once a day. After the first two weeks the dose increases to two 200mg tablets daily, split into one tablet every 12 hours. The dose should NOT be increased though if there are any symptoms of rash.

If you get a rash with nevirapine, you should make sure your doctor checks this carefully. Everyone starting nevirapine should visit their clinic every two weeks for the first two months to check for liver toxicity, so getting a rash examined should be very easy.

Approximately 5% of people discontinue nevirapine due to a rash.

Anything more than a mild rash may require stopping nevirapine – but only on the advice of your doctor.

More serious rash (reported in 0.5% of cases) can be life-threatening (Stevens-Johnson Syndrome) and can be dependent on how early nevirapine is discontinued. This is why getting an expert medical assessment when a rash appears is essential.

Abacavir and rash

A rash can sometimes be one of the symptoms of the hypersensitivity reaction associated with abacavir (Ziagen, Kivexa and Trizivir) that occurs in 4–5% of people using abacavir.

It is very important that you see your doctor if a rash appears when using abacavir in a combination. If abacavir is not stopped – or if it is used again in the future, this can lead to a life-threatening reaction.


This is the web edition of the i-Base guide Avoiding & managing side effects. This guide is available in UK clinics. You can order free printed copies or download a PDF version (564 Kb). There are also several translations. Decisions relating to your treatment should always be taken in consultation with your doctor. Information in this guide is intended to support those discussions

Top | i-Base guides | Home | Order & subscribe | Contact | Site map | Access